Biotech Values

[DewDiligence]

TMC435 has not yet reported bona fide efficacy in phase-2b; rather, the phase-2b trials—PILLAR in the first-line setting (#msg-52204240) and ASPIRE in the second-line setting (#msg-56867553)—have completed 24 weeks of dosing in all arms. There are not yet any SVR data in either phase-2b trial, although the 24-week on-treatment data look quite good.

I don’t have an answer for you about phototoxicity. Medivir did not mention it on the webcast, and none of the analysts asked about it despite their extensive questioning about other aspects of the program.